Christy Franco
Commercial & Manufacturing Strategy SME Sweetgrass Bio
Seminars
Thursday 26th March 2026
Roundtable Discussion: Process Economics in DNA Manufacturing: Clinical vs. Commercial Perspectives
10:10 am
- Distinguishing pre-clinical and clinical-stage manufacturing (“quick and dirty”) vs commercial production (cost-efficient, scalable, validated)
- Cost of goods analysis: when is cost reduction critical, and when can it be deprioritized?
- Impact of company size: regulatory trust in large pharma vs. hurdles faced by small biotechs
- Economic implications of synthetic DNA adoption for individualized vs. largepopulation therapies
